JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 JPET FastThis articleForward. has not Published been copyedited on and January formatted. 24,The final2003 version as DOI:10.1124/jpet.102.047407 may differ from this version.
Inhibitor Binding to Type 4 Phosphodiesterase (PDE4) Assessed
Using [3H]-Piclamilast and [3H]-Rolipram
Yu Zhao, Han-Ting Zhang, and James M. O’Donnell
Department of Pharmacology
University of Tennessee Health Science Center Downloaded from
Memphis, Tennessee jpet.aspetjournals.org at ASPET Journals on September 27, 2021
1
Copyright 2003 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Running title: Inhibitor binding to PDE4
Correspondence should be addressed to:
James M. O’Donnell, Ph.D.
Department of Pharmacology
University of Tennessee Health Science Center
874 Union Avenue Downloaded from
Memphis, TN 38163 jpet.aspetjournals.org Phone: 901-448-3621
Fax: 901-448-3849
Email: [email protected] at ASPET Journals on September 27, 2021
Number of text page: 31
Number of tables: 3
Number of figures: 7
Number of references: 50
Number of words: Abstract (241); Introduction (716); Discussion (1544)
Abbreviations: EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; HARBS, high-affinity rolipram binding site; LARBS, low-affinity rolipram binding site; IBMX, 3-isobutyl-1- methylxanthine; PDE, phosphodiesterase
Section: Neuropharmacology
2 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Abstract
Piclamilast is a PDE4 inhibitor with equal affinity for the high-affinity rolipram binding site (HARBS) and low-affinity rolipram binding site (LARBS). The binding of
[3H]-piclamilast to preparations of rat brain and peripheral tissue was investigated and compared to that of [3H]-rolipram. [3H]-Piclamilast binding was high affinity, saturable, reversible, and partially Mg2+-dependent. Binding was detected both to membrane and Downloaded from soluble fractions, with Kd values of 3.1 and 4.5 nM, respectively. The Bmax values for
[3H]-piclamilast were about 1.5-fold greater than that of [3H]-rolipram binding, suggesting that [3H]-piclamilast, but not [3H]-rolipram, binds to LARBS as well as jpet.aspetjournals.org HARBS. The HARBS was present in all the brain regions examined, but not in peripheral tissues. All PDE4 inhibitors tested were potent competitors for [3H]-
piclamilast binding; the competition curves for rolipram, desmethylpiclamilast, ICI at ASPET Journals on September 27, 2021
63,197, Ro 20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site model. Inhibitors of other PDE families were much less potent. The inhibition of [3H]-piclamilast was further tested in the presence of 1 mM rolipram in order to isolate the LARBS. Under this condition, the competition curves for all the inhibitors were
adequately described by a one-site model, with Ki values close to that for the LARBS.
The results indicated that [3H]-piclamilast is a useful tool to directly study inhibitor interaction with the HARBS and the LARBS in rat brain.
3 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Introduction
Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze the second messengers cyclic AMP and cyclic GMP. The mammalian PDEs have been classified into eleven families (Francis et al., 2001; Soderling and Beavo, 2000; Manganiello et al., 1995; Conti et al., 1999). The PDE4 family, encoded by four genes (PDE4A-D), is characterized by
its low Km value for cAMP and its sensitivity to inhibition by rolipram (Beavo, 1995;
Beavo et al, 1994; Bolger, 1994). PDE4 inhibitors show promising pharmacological Downloaded from effects in a variety of disease models, particularly asthma and depression (Giembycz,
1996; O’Donnell, 1993; O’Donnell and Frith, 1999; Torphy, 1991). However, central jpet.aspetjournals.org nervous system and gastrointestinal side effects remain a problem, limiting clinical development. It has been speculated that some of the side effects may be mediated
through inhibitor interaction with the high-affinity rolipram binding site (HARBS) on at ASPET Journals on September 27, 2021
PDE4 (Duplantier et al., 1996; Barnette et al., 1995); rolipram and a number of other
PDE4 inhibitors have been shown to bind with low nanomolar affinity to this site
(Schneider et al, 1986; Torphy et al., 1992; Jacobitz et al., 1996).
In addition to binding to the HARBS, PDE4 inhibitors also bind to a low-affinity state, termed the low-affinity rolipram binding site (LARBS). It should be noted that the terminology of HARBS and LARBS refers specifically to rolipram binding. Some inhibitors bind with high affinity to both the HARBS and the LARBS (e.g., piclamilast).
A study using truncated PDE4A mutants indicated that inhibitor binding to both the
HARBS and the LARBS is to the catalytic site (Jacobitz et al., 1996). Binding to the
HARBS, but not the LARBS, depends on the presence of N-terminal region. While their exact natures are still unclear, it appears the HARBS and the LARBS are more accurately
4 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
described as two distinct binding affinity states, rather than separate sites (Schneider et al,
1986; Torphy et al., 1992; Souness and Scott, 1993; Jacobitz et al., 1996).
Interestingly, the rank-order potency of a variety of compounds for inhibiting
PDE4 catalytic activity differs from their rank-order potency for competing with [3H]- rolipram binding to the HARBS (Torphy et al, 1992; Baures et al., 1993). Although the function of the HARBS is unknown, the potency of PDE4 inhibitors to produce certain effects, such as emesis and increased gastric acid secretion, correlates with their ability to Downloaded from displace [3H]-rolipram from this site. Other effects are more related to their ability to inhibit PDE4 catalytic activity in a cell-free system, which provides an index of inhibitor jpet.aspetjournals.org interaction with the LARBS (Duplantier et al, 1996; Harris et al., 1989; Barnette et al.,
1995; Barnette et al., 1996; Souness et al, 1996). These findings suggest that the
pharmacological effects that result from the interaction of inhibitors with the HARBS and at ASPET Journals on September 27, 2021 the LARBS are distinct. This is particularly evident when one compares the effects of piclamilast (RP 73,401) and rolipram. Piclamilast is about 1000-fold more potent than rolipram for inhibiting guinea pig smooth muscle PDE4, but only about 4-fold more potent for inhibiting methacholine-induced contraction of guinea-pig trachealis muscle or enhancing isoproterenol-stimulated cyclic AMP formation in guinea-pig eosinophils
(Ashton et al., 1994; Souness et al., 1995).
Piclamilast is a selective and potent PDE4 inhibitor (Karlsson et al, 1993; Ashton
et al., 1994). PDE4 isolated from various cell types is inhibited by piclamilast with a Ki of about 1 nM (Ashton, 1994). Piclamilast displays similar potency for inhibition of
PDE4 regardless of the source and the procedure used to prepare the enzyme; rolipram potency, by contrast, is dependent on such factors (Schneider et al, 1986; Schwabe et al.,
5 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
1976; Fredholm et al., 1979; Ruckstuhl and Landry, 1981; Lugnier et al., 1983; Davis,
1984). Piclamilast does not exhibit differential affinity for the HARBS and the LARBS; it binds with low nanomolar affinity to both states of PDE4 (Souness et al., 1995).
Rolipram, by contrast, exhibits approximately 500-fold greater affinity for the HARBS relative to the LARBS (Schneider et al, 1986; Torphy et al, 1992; Jacobitz et al., 1996).
Thus, [3H]-piclamilast appears to be a useful tool to directly study inhibitor interaction with the high- and low-affinity binding sites on PDE4. The present study was conducted Downloaded from to characterize the binding of [3H]-piclamilast in rat brain, to compare it with [3H]- rolipram binding, and to determine the affinity of PDE4 inhibitors for the HARBS and jpet.aspetjournals.org the LARBS using these two radioligands. at ASPET Journals on September 27, 2021
6 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Materials and Methods
Animals. Male Sprague-Dawley rats (Harlan, Indianapolis, IN, U.S.A.) were housed in a temperature- (22-24°C) and light- (on 6:00 a.m. - 6:00 p.m.) controlled room and were allowed free assess to food pellets and water. Their use in studies reported in this article have been carried out in accordance with the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the National Institutes of Health and have been approved by the Animal Care and Use Committee of the University of Tennessee Health Downloaded from
Science Center.
Radioligand binding assays. Rats were killed by decapitation. Brain regions (cerebral jpet.aspetjournals.org cortex, hippocampus, amygdala, hypothalamus, neostriatum, cerebellum, and brain stem) and peripheral tissues (heart, liver, and skeletal muscle) were dissected on ice and
homogenized in binding buffer (50 mM Tris HCl, 5 mM MgCl2, pH 7.5) using a Polytron at ASPET Journals on September 27, 2021 homogenizer. Separation of supernatant and particulate fractions was achieved by centrifugation at 15,000 g for 15 minutes; the pellet then was resuspended in binding buffer.
[3H]-Rolipram and [3H]-piclamilast binding was measured by a modification of the method of Schneider and co-workers (1986). Membrane or cytosolic preparations containing 200 – 300 mg protein were incubated in duplicate at 30°C in 250ml of binding buffer containing [3H]-rolipram or [3H]-piclamilast. Nonspecific binding was defined in the presence of 10 mM unlabeled Ro 20-1724 for [3H]-rolipram binding or 1 mM unlabeled rolipram for [3H]-piclamilast binding. Reactions were stopped after 1 hr by the addition of 5 ml of ice-cold binding buffer and rapid vacuum filtration through glass fiber
7 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
filters that had been soaked in 0.3% polyethyleneimine. The filters were washed twice with 5 ml of ice-cold buffer, and radioactivity measured by liquid scintillation counting.
For the saturation binding studies, different concentrations of [3H]-rolipram (0.5 -
50 nM) and [3H]-piclamilast (0.01 - 20 nM) were used. For the competition studies, a 2 nM concentration of [3H]-rolipram or [3H]-piclamilast was used in the presence of different concentrations of unlabeled inhibitors.
Statistical analysis. Data were analyzed by nonlinear regression to determine whether Downloaded from inhibitor binding to PDE4 was better described by an interaction with one or two binding sites (Draper and Smith, 1966; O’Donnell et al., 1984). Binding to a single site was jpet.aspetjournals.org assumed unless the data were better described by a two-site binding equation. This was indicated when the residual sum of square was reduced significantly (F ratio, p < 0.01).
Bmax and Kd values were determined for saturation experiments. EC50 values were at ASPET Journals on September 27, 2021 determined for competition experiments; Ki values were calculated from EC50 values using the method of Cheng and Prusoff (1973). All values are expressed as means ±
S.E.M. from at least three independent experiments carried out in duplicate.
Materials. [3H]-Rolipram was purchased from American Radiolabeled Chemicals Inc.
(St. Louis, MO, U.S.A.). [3H]-Piclamilast was a gift from GlaxoSmithKline (Valley
Forge, PA, U.S.A.). Piclamilast was provided by Aventis Pharmaceuticals (Vitry sur
Seine, France). Desmethylpiclamilast, cilomilast, and roflumilast were provided by
Memory Pharmaceuticals (Montvale, NJ, U.S.A.). Rolipram was provided by Schering
AG (Berlin, Germany). Milrinone and zaprinast were purchased from Calbiochem (La
Jolla, CA, U.S.A.). Other drugs and chemicals were obtained from Fisher Scientific
(Dallas, TX, U.S.A.) or Sigma Chemical Co. (St. Louis, MO, U.S.A.).
8 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Results
Association and dissociation. Specific binding of [3H]-piclamilast at 30°C increased rapidly to reach maximal binding in about 2 minutes, with a half-time of association of 24 seconds, after which binding remained stable up to 2 h (Fig. 1). Dissociation of [3H]- piclamilast, determined following the addition of 1 mM rolipram, was equally rapid, with a half-time of 11 seconds (Fig. 1). The amount of radioactivity bound reached the level of nonspecific binding within 3 minutes of the addition of rolipram. By contrast, the Downloaded from association of [3H]-rolipram was better described by a two-phase model, with half-times of association of 24 seconds and 40 minutes. The dissociation of [3H]-rolipram was jpet.aspetjournals.org relatively slow, with a half-time of 6 minutes (Fig. 1).
Mg2+ -dependence. Binding of [3H]-piclamilast (2 nM) and [3H]-rolipram (2 nM) was
2+ 2+
determined at three concentrations of Mg (Fig. 2). Mg increased the specific binding at ASPET Journals on September 27, 2021 of both radioligands in a concentration-dependent manner. In the presence of 5 mM
Mg2+, the specific binding of [3H]-piclamilast was about 4-fold higher than the specific binding in the absence of Mg2+; for rolipram, the Mg2+-dependent increase was about 3- fold.
Saturation binding. Saturation binding of [3H]-piclamilast and [3H]-rolipram was carried out using whole homogenate of rat cerebral cortex, as well as crude membrane and soluble (i.e., cytosolic) fractions (Fig. 3; Table 1). Specific binding of both [3H]- piclamilast and [3H]-rolipram to homogenate, membrane, and cytosolic preparations of rat cerebral cortex was saturable and of high affinity. Using non-linear regression analysis, the binding of each radioligand was found to be adequately described by a one-
3 site model. Adjusted for protein content, the Bmax values for [ H]-piclamilast binding to
9 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
membranes and whole homogenate were similar; the Bmax value for binding to the cytosolic fraction was slightly less, but the difference was not significant.
3 3 Compared to that of [ H]-rolipram binding, the Bmax value for [ H]-piclamilast binding was about 1.5-fold greater in all three preparations. For [3H]-rolipram binding, the affinity was higher to membranes than to cytosolic and whole homogenate
preparations (Kd =4.8±0.5, 12.1±2.2, and 19.2±10.1 nM, respectively); the Kd values obtained using membrane and cytosolic fractions were significantly different (p<0.05). Downloaded from
3 By contrast, [ H]-piclamilast exhibited similar affinity for all the fractions (Kd =3.1±0.2,
4.5±1.1, and 6.7±2.3 nM, respectively). For membrane and cytosolic preparations, the Kd jpet.aspetjournals.org values for [3H]-rolipram and [3H]-piclamilast differed significantly (p<0.05).
Distribution of high- and low-affinity sites. [3H]-Piclamilast binding to preparations of
various regions of brain and peripheral tissues was determined in the presence of at ASPET Journals on September 27, 2021 different concentrations of rolipram. Data were analyzed by nonlinear regression to assess potential one- or two-site binding. Rolipram inhibition using preparations of the brain regions was better described by a two-site model, while the inhibition using the peripheral tissue preparations was adequately described by a one-site model (Fig. 4;
Table 2). In all the brain regions examined, approximately 60% of the total specific binding was to the high-affinity binding site; this was quite consistent across the different regions as well as for homogenate, membrane, and cytosolic preparations. High-affinity binding was not detected in peripheral tissues (Fig. 4; Table 2). The affinity values for the binding of rolipram to the low-affinity binding site were consistent for all the brain regions and the peripheral tissues, except for liver, for which an almost 100-fold lower affinity was observed.
10 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Inhibition of [3H]-piclamilast and [3H]-rolipram binding. A variety of specific PDE4 inhibitors and inhibitors of other PDE families were tested for their potency to inhibit
3 3 [ H]-piclamilast and [ H]-rolipram binding to rat cerebral cortical membranes; the Ki values are shown in Table 3. For [3H]-piclamilast binding (Fig. 5), the competition curves for rolipram, desmethylpiclamilast, ICI 63,197, Ro 20-1724, and cilomilast were better described by a two-site model; the competition curves for piclamilast, roflumilast, and CDP 840 were adequately described by a one-site model. For those inhibitors that Downloaded from
bound to two sites, the Ki values for the high-affinity interaction were all in the
nanomolar range, while the Ki values for low-affinity interaction were all in the low jpet.aspetjournals.org micromolar range.
All the curves for inhibition of [3H]-rolipram binding by PDE4 inhibitors were
adequately described by a one-site model, with Ki values in the low-to-mid-nanomolar at ASPET Journals on September 27, 2021 range (Fig. 6). For inhibition of [3H]-rolipram binding, piclamilast was the most potent, followed by roflumilast, rolipram, desmethylpiclamilast, cilomilast, Ro 20-1724, ICI
63,197, and CDP 840. Inhibition of [3H]-piclamilast binding for some inhibitors was tested in the presence of 1 mM rolipram, in order to isolate the LARBS (Fig. 7). The competition curves under this condition all were consistent with a one-site model.
Some non-PDE4 inhibitors were tested against both [3H]-piclamilast and [3H]- rolipram binding. The inhibition of the binding of each radioligand by non-PDE4 inhibitors was similar (Table 3). Milrinone, trequinsin, and papaverine inhibition of both
3 3 [ H]-piclamilast and [ H]-rolipram was adequately described by a one-site model, with Ki values in the low micromolar range; similar data were obtained with the nonselective
11 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
PDE inhibitor IBMX. Vinpocetine, EHNA, and zaprinast, at a concentration of 1 mM, inhibited less than 50% of the total specific binding of either radioligand. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
12 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Discussion
In the present study, the binding of [3H]-piclamilast to preparations of rat brain was compared with that of [3H]-rolipram. The results indicated that [3H]-piclamilast labels both the LARBS and the HARBS with high affinity. [3H]-Rolipram, by contrast, at the concentration range examined, bound only to the HARBS.
Studies have investigated the relationship between the biological effects of PDE4 inhibitors and their interaction with the HARBS and the LARBS (Souness et al, 1996; Downloaded from
Souness et al, 1995; Souness et al 1999; Barnette et al., 1996; Duplantier et al., 1996;
Kelly et al., 1996). In most of these studies, inhibition of [3H]-rolipram binding is used to jpet.aspetjournals.org evaluate affinity for the HARBS, while inhibition of PDE4 hydrolytic activity in a cell- free system is used to evaluate affinity for the LARBS. The LARBS is difficult to study
3
using [ H]-rolipram binding. at ASPET Journals on September 27, 2021
Jacobitz and the colleagues (1996) used an equilibrium filtration technique to detect both low- and high-affinity rolipram binding. Using this method, the filter washing protocol is eliminated. Because the ligand/receptor complex is not diluted during the separation procedure, the equilibrium condition is maintained and the ligand bound to the low-affinity site does not dissociate. However, as a consequence, nonspecific binding in this assay is highly variable. Equilibrium dialysis is another method used to study the LARBS (Rocque et al., 1997). Using this method, a true equilibrium binding constant can be measured. However, a high protein concentration is required in order to obtain an adequate signal to noise ratio.
Recombinant systems that express either high- or low-affinity conformations of
PDE4 have been developed to evaluate inhibitors (Bardelle et al., 1999; Rodger et al.,
13 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
1999). PDE4A330, a PDE4A truncate, expressed in CHO cells exhibits only the low- affinity conformation, while PDE4A4, 4B2, 4C2, and 4D3 all adopt a high-affinity binding conformation for rolipram. These systems can be used to screen and optimize inhibitors against the low-affinity conformation of PDE4.
Piclamilast is a selective and very potent PDE4 inhibitor (Karlsson et al, 1993;
Ashton et al., 1994). In contrast to rolipram, piclamilast binds with high affinity to both the HARBS and the LARBS (Souness et al., 1995). Thus, [3H]-piclamilast is a potential Downloaded from tool to study the LARBS as well as HARBS. The association and dissociation of [3H]- piclamilast were both fast and exhibited first-order kinetics, which is consistent with the jpet.aspetjournals.org saturation binding data. By contrast, the association of [3H]-rolipram binding was better described by two-component model; its dissociation, however, was adequately described
by a one-site model. Previously, Schneider and coworkers (1986) reported that both the at ASPET Journals on September 27, 2021 association and dissociation of rolipram binding are biphasic.
At the active site of PDE4, there are two divalent metal ions in a binuclear motif that are involved in both cAMP binding and catalysis (Xu et al., 2000; Laliberte et al.,
2000). [3H]-Rolipram binding is Mg2+-dependent (Schneider et al., 1986). It has been suggested that the HARBS and the LARBS are the consequence of PDE4 binding to its metal cofactor such as Mg2+ (Laliberte et al., 2000). Mg2+, Mn2+, and Co2+ all stabilize high-affinity rolipram binding to the PDE4 holoenzyme. In the absence of the divalent cations, only low-affinity rolipram binding to the apoenzyme is detected (Liu et al.,
2001). Furthermore, in vitro, PKA phosphorylation of PDE4A4, which shifts the potencies of (R)/(S)-rolipram towards their holoenzyme binding affinities, activates the enzyme by increasing its sensitivity to the Mg2+ cofactor. Piclamilast exhibits equal
14 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
affinity for the HARBS and the LARBS. However, in the present study, piclamilast binding to PDE4 was increased in the presence of Mg2+. Huang and co-worker (2000) also found that piclamilast binds preferentially to the holoenzyme. This suggests that
Mg2+ -dependence of inhibitor binding does not fully predict the nature of inhibitor interaction with the HARBS and the LARBS.
3 3 [ H]-Piclamilast binding was saturable and reversible. The Bmax value for [ H]- piclamilast was about 1.5-fold greater than that of [3H]-rolipram. Jacobitz and co- Downloaded from
3 workers (1997) reported that the Bmax value for [ H]-piclamilast binding to human recombinant PDE4 was 2-3 fold greater than that for [3H]-rolipram binding. These jpet.aspetjournals.org results likely reflect the fact that [3H]-piclamilast binds to both the HARBS and the
LARBS at nanomolar concentrations, while [3H]-rolipram only binds to HARBS at these
3
concentrations. The saturation curve for [ H]-piclamilast binding, however, was at ASPET Journals on September 27, 2021 consistent with a one-site model, suggesting that piclamilast binds to the two sites with similar affinity.
Schneider and the coworkers (1986) reported that the maximal [3H]-rolipram binding to membranes was higher than that to the cytosolic preparations. In the present
3 3 study, the Bmax value for both [ H]-piclamilast and [ H]-rolipram binding to membranes tended to be higher than to the cytosolic fractions; however, these difference were not
3 significant. The Kd values for [ H]-piclamilast binding to whole homogenate, membrane,
3 and cytosolic preparations were similar, while [ H]-rolipram exhibited a lower Kd value for binding to the membrane fraction than to the cytosolic fraction or whole homogenate.
Souness and coworkers (1992) reported that the binding of rolipram, but not piclamilast, to eosinophils is altered by solubilization or treatment with vanadate/glutathione. These
15 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
results suggest that the affinity of rolipram binding, but not that of piclamilast, is
3 sensitive to the conformational state of PDE4. The difference in Kd values for [ H]- rolipram binding to membrane and cytosolic fractions may be due in part to the differential expression pattern of PDE4 variants. For example, PDE4A1 is expressed solely in membrane fractions, while PDE4A5 is present in both membrane and cytosolic fractions (McPhee et al., 1995; Pooley et al., 1997; Huston et al., 1996). Slight differences in affinity for the differentially distributed variants could translate into a Downloaded from
difference in Kd values. In addition, association of PDE4 with membrane-associated proteins such as RACK might result in a different rolipram affinity for membrane and jpet.aspetjournals.org cytosolic preparations containing PDE4 (Yarwood et al., 1999).
All the brain regions tested exhibited the HARBS, with the percentage varying
from 47 to 66%. By contrast, the HARBS was not detected in peripheral tissues. The at ASPET Journals on September 27, 2021
HARBS in rat brain was first demonstrated by Schneider and coworkers (1986). They reported that the peripheral organs tested showed either no detectable [3H]-rolipram binding or a very low specific binding capacity. While the nature of the HARBS is not yet clear, it has been suggested to be one of the two distinct conformations of PDE4
(Torphy et al., 1992; Souness and Scott, 1993). Consistent with this interpretation, the present results showed that the rolipram competition curve for [3H]-piclamilast is biphasic, indicating [3H]-piclamilast labels two sites on PDE4 that exhibit different affinities for rolipram. [3H]-piclamilast showed the highest total binding in hippocampus.
The binding also was high in hypothalamus, neostriatum, cerebellum, and amygdala. An autoradiographic study using [3H]-rolipram binding revealed high binding densities for
16 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
the HARBS in the cerebellum, olfactory bulb, frontal cortex, subiculum, and the CA1 region of hippocampus (Kaulen et al., 1989).
For [3H]-piclamilast binding, the competition curves for rolipram, desmethylpiclamilast, ICI 63,197, Ro 20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site model. For those inhibitors that bound differentially to two states, there was approximately 100-fold greater affinity for the HARBS compared Downloaded from
to the LARBS. Ki1 values, which represent binding to the HARBS, exhibited more
variability compared to Ki2 values, which represent binding to the LARBS. The jpet.aspetjournals.org competition curve for piclamilast was adequately described by a one-site model. This is consistent with the finding from saturation analyses that piclamilast binds to both sites
with equal affinity. The potency order of PDE4 inhibitors tested in this study was in at ASPET Journals on September 27, 2021 agreement with the potency orders of these inhibitors reported previously for inhibition of enzyme activity (Schneider et al., 1986, Souness et al., 1999, Souness et al., 1997; Saldou et al, 1998). The competition curves for [3H]-rolipram binding all were adequately described by a one-site model, with a potency order that was the same as that for inhibition of [3H]-piclamilast binding. The inhibition of [3H]-piclamilast and [3H]- rolipram binding by non-PDE4 inhibitors were less potent and showed no significant differences between the two radioligands. Consistent with their low binding affinities, these drugs also have been shown to be very poor inhibitors of PDE4 enzymatic activity
(Makhay et al., 2001; Schneider et al., 1986; Souness and Scott, 1992).
The LARBS can be studied directly using [3H]-piclamilast binding in the presence of 1 mM rolipram, which blocked more than 90% of the ligand binding to the HARBS.
17 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
3 The remaining [ H]-piclamilast binding was further inhibited by PDE4 inhibitors with Ki values in micromolar range and with competition curves consistent with a one-site model.
These Ki values were close to the Ki2 values from the competition study carried out in the absence of 1 mM rolipram, which represent the binding affinity for the LARBS. These results indicate that while [3H]-piclamilast binds to both the LARBS and the HARBS, inhibitor affinity for the LARBS can be evaluated using [3H]-piclamilast in the presence of a proper concentration of rolipram. Downloaded from
In summary, it has been shown that [3H]-piclamilast labels both the LARBS and the HARBS of PDE4 in rat brain with similar affinity. [3H]-piclamilast binds only to the jpet.aspetjournals.org LARBS, when the HARBS is blocked with a low concentration of rolipram. All these properties should make [3H]-piclamilast a useful tool to study the interaction of PDE4
inhibitors with the LARBS, in order to assess the relationship between inhibitor at ASPET Journals on September 27, 2021 interactions with this site and their pharmacological effects.
18 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Acknowledgements
We thank Dr. David Edwards (GlaxoSmithKline Pharmaceuticals) for providing [3H]- piclamilast and Dr. Allen Hopper (Memory Pharmaceuticals) for synthesizing desmethylpiclamilast. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
19 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
References
Allen RA, Merriman MW, Perry MJ, Owens RJ (1999) Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors. Biochem Pharmacol 57: 1375-1382.
Ashton MJ, Cook DC, Fenton G, Karlsson JA, Palfreyman MN, Raeburn D, Ratcliffe AJ,
Souness JE, Thurairatnam S, Vicker N (1994) Selective type IV phosphodiesterase Downloaded from inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-
(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem 37:1696-1703. jpet.aspetjournals.org
Bardelle C, Smales C, Ito M, Nomoto K, Wong EY, Kato H, Saeki T, Staddon JM (1999)
Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for at ASPET Journals on September 27, 2021 inhibitors. Anal Biochem 275:148-155.
Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ (1995)
Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396-1402.
Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM,
Prabhakar US, Rush JA, Torphy TJ (1996) Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]-rolipram binding. Biochem Pharmacol 51:949-956.
20 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Baures PW, Eggleston DS, Erhard KF, Cieslinski LB, Torphy TJ, Christensen SB (1993)
The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of
(+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one. J
Med Chem 36:3274-3277.
Beavo JA, Conti M, Heaslip RJ (1994) Multiple cyclic nucleotide phosphodiesterases. Downloaded from
Mol Pharmacol 46:399-405. jpet.aspetjournals.org Beavo JA. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748. at ASPET Journals on September 27, 2021
Bolger GB (1994) Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 6:851-859.
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases.
Prog Nucleic Acid Res Mol Biol 63:1-38.
21 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Davis CW (1984) Assessment of selective inhibition of rat cerebral cortical calcium- independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochim Biophys Acta 797:354-362.
Draper NR and Smith H (1966) Applied Regression Analysis, John Wiley & Sons, New
York. Downloaded from
Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF,
Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, Watson JW (1996) jpet.aspetjournals.org Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus
[3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
J Med Chem 39:120-125. at ASPET Journals on September 27, 2021
Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
Fredholm BB, Brodin K, Strandberg K (1979) On the mechanism of relaxation of tracheal muscle by theophylline and other cyclic nucleotide phosphodiesterase inhibitors.
Acta Pharmacol Toxicol (Copenh) 45:336-344.
Giembycz MA (1996) Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 17:331-336.
22 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Harris AL, Connell MJ, Ferguson EW, Wallace AM, Gordon RJ, Pagani ED, Silver PJ
(1989) Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther 251:199-206.
Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, Houslay MD
(1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that Downloaded from exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem
271:31334-31344. jpet.aspetjournals.org
Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the
functional domains of human recombinant phosphodiesterase 4A: structural requirements at ASPET Journals on September 27, 2021 for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
Jacobitz S, Ryan MD, McLaughlin MM, Livi GP, DeWolf WE Jr, Torphy TJ (1997) Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A. Mol Pharmacol 51:999-1006.
Karlsson, J.A., Souness, J., Raeburn, D., Palfreyman, M. and Ashton, M (1993) Anti- inflammatory effects of novel selective cyclic nucleotide phosphodiesterase inhibitors. In
T-lymphocyte and Inflammatory cell Research in Asthma ed. Jolles, G., Karlsson, J-A. and Taylor, J., pp. 323-351, Academic Press, London.
23 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Kaulen P, Bruning G, Schneider HH, Sarter M, Baumgarten HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229-245.
Kelly JJ, Barnes PJ, Giembycz MA (1996) Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R- (-)-rolipram binding by selective inhibitors. Biochem J 318:425- Downloaded from
436. jpet.aspetjournals.org Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A,
Gorseth E, Gresser M, Huang Z (2000) Conformational difference between PDE4
apoenzyme and holoenzyme. Biochemistry 39:6449-6458. at ASPET Journals on September 27, 2021
Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser
MJ, Huang Z (2001) Dissecting the cofactor-dependent and independent bindings of
PDE4 inhibitors. Biochemistry 40:10179-10186.
Lugnier C, Stierle A, Beretz A, Schoeffter P, Lebec A, Wermuth CG, Cazenave JP,
Stoclet JC (1983) Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity. Biochem Biophys Res Comm 113:954-959.
24 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Makhay MM, Houslay MD, O’Donnell JM (2001) Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology 158:297-304.
McPhee I, Pooley L, Lobban M, Bolger G, Houslay MD (1995) Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J 310:965-
974. Downloaded from
Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E (1995) Diversity in cyclic jpet.aspetjournals.org nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 322:1-13.
O'Donnell JM (1993) Antidepressant-like effects of rolipram and other inhibitors of at ASPET Journals on September 27, 2021 cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 264:1168-1178.
O'Donnell JM, Wolfe BB, Frazer A (1984) Agonist interactions with beta adrenergic receptors in rat brain. J Pharmacol Exp Ther 228:640-647.
O'Donnell JM, Frith S (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185-192.
25 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Pooley L, Shakur Y, Rena G, Houslay MD (1997) Intracellular localization of the
PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Biochem J 321:177-185.
Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel
IR, Wisely GB, Clay WC, Kadwell SH, Hoffman CR, Luther MA (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two Downloaded from affinities. Biochemistry 36:14250-14261. jpet.aspetjournals.org Ruckstuhl M, Landry Y (1981) Inhibition of lung cyclic AMP- and cyclic GMP- phosphodiesterases by flavonoids and other chromone-like compounds. Biochem
Pharmacol 30:697-702. at ASPET Journals on September 27, 2021
Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L,
Callan O, Su C, Jarnagin K, Shelton ER (1998) Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal 10:427-440.
Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
Schwabe U, Miyake M, Ohga Y, Daly JW (1976) 4-(3-Cyclopentyloxy-4- methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'- monophosphate phosphodiesterases in homogenates and tissue slices from rat brain.
26 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Mol Pharmacol 12:900-910.
Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
Souness JE, Maslen C, Scott LC (1992) Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP- Downloaded from specific phosphodiesterase. FEBS Lett 302:181-184. jpet.aspetjournals.org Souness JE, Scott LC (1993) Stereospecificity of rolipram actions on eosinophil cyclic
AMP-specific phosphodiesterase. Biochem J 291:389-395. at ASPET Journals on September 27, 2021
Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ,
Karlsson JA (1995) Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Br J Pharmacol 115:39-46.
Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN,
Karlsson JA (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress
TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 118:649-658.
27 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Souness JE, Houghton C, Sardar N, Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 121:743-
750.
Souness JE, Houghton C, Sardar N, Withnall MT (1999) Suppression of anti-CD3- induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti- Downloaded from infected BALB/c mice by phosphodiesterase 4 inhibitors. Biochem Pharmacol 58:991-
999. jpet.aspetjournals.org
Torphy TJ, Undem BJ (1991) Phosphodiesterase inhibitors: new opportunities for the
treatment of asthma. Thorax 46:512-523. at ASPET Journals on September 27, 2021
Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, Livi GP
(1992) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798-1804
Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ,
Milburn MV, Zhao Y, Ke H (2000) Nolte RT. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288:1822-1825.
28 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase
PDE4D5 isoform. J Biol Chem 274:14909-14917. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
29 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Footnotes
a. This work was supported by research grants and an Independent Scientist Award
from the National Institute of Mental Health.
Meeting presentation:
Characterization of the binding of [3H]-piclamilast to rat cerebral cortex, comparison Downloaded from
with [3H]-rolipram; Gordon Research Conference on Cyclic Nucleotide
Phosphodiesterases, South Hadley, Massachusetts, 2002 jpet.aspetjournals.org
b. Send reprint requests to: at ASPET Journals on September 27, 2021
Dr. James M. O’Donnell
Department of Pharmacology
University of Tennessee Health Science Center
874 Union Ave.
Memphis, TN 38163
30 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Table 1
[3H]-Piclamilast and [3H]-rolipram binding to whole homogenate,
membrane, and cytosolic preparations of rat cerebral cortex
[3H]-Rolipram [3H]-Piclamilast
Whole Membrane Cytosolic Whole Membrane Cytosolic
a Bmax (fmol/mg protein) 273.3±31.8 280.0±16.5 210.0±20.0 430.0±28.9 453.0±18.6 373.3±63.3 Downloaded from
a * Kd (nM) 19.2±10.1 4.8±0.5 12.1±2.2 6.7±2.3 3.1±0.2 4.5±1.1 jpet.aspetjournals.org
% HARBS 100 a 100 100 62.1±1.0 58.7±4.2 63.3±9.2 at ASPET Journals on September 27, 2021
a Values shown are Bmax and Kd values and percentage binding to the HARBS (mean ±
SEM) from at least three independent experiments, determined by nonlinear regression
(Draper and Smith, 1966; O’Donnell et al., 1984).
*Significantly different from corresponding value obtained using membrane preparations,
p<0.05.
31 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Table 2
Binding of [3H]-piclamilast to membrane
preparations of rat brain regions and peripheral tissues
Tissue [3H]-Piclamilast bounda %HARB Rolipram Inhibition
(fmol/mg protein) Ki1 (nM) Ki2 (mM)
Hippocampus 432.4±49.7b 60.0±2.0 4.6±0.5b 0.7±0.1b
Cerebral cortex 149.7±9.9 58.7±4.2 8.4±2.2 0.8±0.2 Downloaded from
Amygdala 178.8±5.6 66.7±0.3 33.9±15.5 2.1±0.6
Hypothalamus 267.1±14.7 47.7±4.7 22.7±12.1 1.4±0.3 jpet.aspetjournals.org
Neostriatum 217.2±20.1 62.0±2.5 6.6±1.0 0.7±0.1
Cerebellum 203.2±25.3 60.3±2.7 5.7±1.4 0.4±0.06
Brain stem 113.9±6.0 53.1±3.5 1.2±0.3 0.8±0.03 at ASPET Journals on September 27, 2021
Liver 91.3±18.9 0 65.1±10.7
Heart 45.8±5.2 0 0.2±0.04
Skeletal muscle 18.02±1.5 0 0.4±0.01
a Membrane preparations from different tissues were incubated with 2 nM [3H]- piclamilast in the presence of different concentrations of rolipram.
b Total binding and Ki values for rolipram inhibition were calculated by nonlinear regression (Draper and Smith, 1966; O’Donnell et al., 1984). The data shown are from at least three separate experiments (mean ± SEM).
32 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Table 3
Ki values for PDE4 inhibitors and non-PDE4 inhibitors determined
from competition assays using [3H]-piclamilast and [3H]-rolipram binding to
rat cerebral cortical membranesa
Inhibitors [3H]-rolipram [3H]-piclamilast [3H]-piclamilast +
Ki (nM) Ki1 (nM) Ki2 (mM) 10 µM rolipram
b Downloaded from Ki (mM)
Piclamilast 0.04±0.01 0.3±0.02 0.009±0.0006
Roflumilast 2.4±0.5 1.5±0.06 0.003±0.0006 jpet.aspetjournals.org
DMP 34.8±3.5 6.0±2.0 0.8±0.1 0.6±0.3
Rolipram 16.6±8.2 12.7±4.8 1.4±0.5 4.1±1.0
Ro 20-1724 189.1±13.0 114.0±19.9 7.1±2.9 14.7±5.7 at ASPET Journals on September 27, 2021
ICI 63,197 312.9±8.3 154.6±12.5 10.6±0.5 32.0±2.5
Cilomilast 117.8±27.0 0.2±0.02 c 0.2±0.06
CDP 840 1,252.7±537.6 0.8±0.1 0.9±0.06
Trequinsin 3,151.5±66.7 3.1±0.6 44.8±3.3
IBMX 3,090.9±181.8 7.9±0.06 8.4±1.4 Papaverine 8,821.4±957.1 73.6±1.4 193.3±37.6 Milrinone 92,285±6,347.1 12.8±0.9 30.7±7.4 Vinpocetine >1 mM >1 mM EHNA >1 mM >1 mM Zaprinast >1 mM >1 mM
33 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Table 3 (continued) a Rat cerebral cortical membranes were incubated with 2 nM [3H]-piclamilast or 2 nM
[3H]-rolipram in the presence of different concentrations of PDE4 inhibitors and non-
PDE4 inhibitors. Ki values were calculated from IC50 values (Cheng and Prusoff, 1973), which were determined by nonlinear regression (Draper and Smith, 1966; O’Donnell et al., 1984). Results are from at least three separate experiments (mean ± SEM). Downloaded from b Rat cerebral cortical membranes were incubated with 2 nM [3H]-piclamilast in the presence of 1 mM rolipram, in order to isolate the LARBS, and different concentrations jpet.aspetjournals.org of PDE inhibitors.
c
When inhibition was adequately described by a one-site model, the Ki values are at ASPET Journals on September 27, 2021
included with either the Ki1 or Ki2 values. Ki values less than 100 nM are listed as Ki1 values; those greater than 100 nM are listed as Ki2 values.
34 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure legends
Figure 1. Time course of association (A, C) and dissociation (B, D) of [3H]-piclamilast and [3H]-rolipram binding. Rat cerebral cortical membranes were incubated at 30°C with either 2 nM [3H]-piclamilast or [3H]-rolipram. Association was started by the addition of membranes. Dissociation was started by addition of 1 mM rolipram after 1 h preincubation with either 2 nM [3H]-piclamilast or [3H]-rolipram. Binding was terminated by rapid filtration at different times. Results are from at least three Downloaded from independent experiments (mean ± SEM). jpet.aspetjournals.org Figure 2. Mg2+-dependent binding of [3H]-piclamilast and [3H]-rolipram. Rat cerebral cortical membranes were incubated with either 2 nM [3H]-piclamilast (A) or 2 nM [3H]-
2+
rolipram (B) in the presence of different concentrations of Mg at 30°C for 1 h. Binding at ASPET Journals on September 27, 2021 was terminated by rapid filtration. Results are from at least three independent experiments (mean±SEM). *Significantly different from value in absence of Mg2+, p<0.05; ** p<0.01.
Figure 3. Saturation analysis of [3H]-piclamilast (A) and [3H]-rolipram (B) binding to membrane preparations of rat cerebral cortex. For [3H]-piclamilast binding, concentrations used were 0.01 to 20 nM. For [3H]-rolipram, concentrations used were 0.5 to 50 nM. Binding was carried out at 30°C for 1 h. Results are from three independent
experiments (mean ± SEM). Bmax and Kd values, determined by nonlinear regression analysis, are shown in Table 1.
35 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 4. Rolipram inhibition of [3H]-piclamilast binding to membranes prepared from rat cerebral cortex, skeletal muscle, liver, and heart. Membranes were incubated with 2 nM [3H]-piclamilast and various concentrations of rolipram at 30°C for 1 h. Data shown are from one of three experiments. The competition curve obtained using cerebral cortical membranes was better described by a two-site model, while the competition curves using the membranes prepared from peripheral tissues were adequately described Downloaded from by a one-site model. Ki values are shown in Table 2.
Figure 5. Inhibition of [3H]-piclamilast binding by PDE4 inhibitors. Rat cerebral jpet.aspetjournals.org cortical membranes were incubated with 2 nM [3H]-piclamilast and various concentrations of inhibitors at 30°C for 1 h. Data shown are from one of three
experiments. The competition curves for rolipram, desmethylpiclamilast, ICI 63,197, Ro at ASPET Journals on September 27, 2021
20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site
model. Ki values are shown in Table 3.
Figure 6. Inhibition of [3H]-rolipram binding by PDE4 inhibitors. Rat cerebral cortical membranes were incubated with 2 nM [3H]-rolipram and various concentrations of inhibitors at 30°C for 1 h. Data shown are from one of three experiments. The competition curves for the PDE4 inhibitors were adequately described by a one-site
model. Ki values are shown in Table 3.
36 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 7. Inhibition of [3H]-piclamilast binding in the presence of 1 mM rolipram (to isolate the LARBS). Rat cerebral cortical membranes were incubated with 2 nM [3H]- piclamilast and 1 mM rolipram, together with various concentrations of different inhibitors at 30°C for 1 h. Data shown are from one of three experiments. 100% binding was defined as that in the presence of 2 nM [3H]-piclamilast and 1 mM rolipram. The competition curves for the PDE4 inhibitors were adequately described by a one-site Downloaded from model. Ki values are shown in Table 3. jpet.aspetjournals.org at ASPET Journals on September 27, 2021
37 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 1
A. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021 B.
38 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 1 (continued)
C. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021 D.
39 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 2
A. Downloaded from jpet.aspetjournals.org
B. at ASPET Journals on September 27, 2021
40 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 3
A. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021 B.
41 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 4 Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
42 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 5 Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
43 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 6 Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
44 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version.
Figure 7 Downloaded from jpet.aspetjournals.org at ASPET Journals on September 27, 2021
45